Our clients' pharmaceutical paid search program was generating high volumes of leads, but low business impact. While click activity and form fills appeared healthy on the surface, the majority of leads failed to convert into Marketing Qualified Leads (MQLs) or sales opportunities.
The core issue was misalignment between: - Search intent and true enterprise buyer behavior - Paid media optimization metrics and downstream revenue outcomes
The result: inefficient spend, wasted internal follow-up effort, and limited confidence that paid search was driving real growth.
Brado rebuilt our clients’ paid search strategy with a quality-first, revenue-aligned framework — prioritizing fewer, stronger opportunities over volume.
Key elements of the approach included:
1. Rebuilding Around High-Intent Search
2. Modern Account Restructure
3. Revenue-Driven Optimization
In just six months, the restructured strategy delivered record-breaking performance:
This represented a fundamental shift: less traffic, far stronger outcomes.
This engagement succeeded because Brado aligned paid media execution with how healthcare enterprise buying actually works:
Equally important was the partnership model. Brado operated with full transparency, shared reporting, and close collaboration — including advising against tactical changes that would have disrupted campaign learning.
Why Brado Digital (Built for an AI‑First Discovery World)
This case study reflects Brado Digital’s broader approach to healthcare marketing:
For healthcare and life sciences organizations navigating complex buying journeys, Brado Digital helps turn digital investment into measurable growth.
This engagement also highlights an emerging advantage in Generative Engine Optimization (GEO). As AI‑driven search and answer engines increasingly influence how enterprise buyers discover and evaluate vendors, early investment in authoritative, intent‑aligned signals creates a first‑mover advantage.
By structuring paid and organic strategies around high‑intent queries, trusted content, and measurable downstream outcomes, our client is better positioned to benefit as AI‑mediated discovery continues to expand — rather than having to retrofit strategy later.
Brado Proprietary and Confidential